Education
About Us
Working with TipRanks
Follow Us
Resmed (RMD)
NYSE:RMD
Earnings Data
Report Date
Apr 23, 2026After Close (Confirmed)
Period Ending
2026 (Q3)Consensus EPS Forecast
2.81Last Year’s EPS
2.37Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple strong operational and financial wins: double-digit headline revenue growth, expanded margins driven by supply-chain productivity, robust device and mask growth, healthy cash generation, continued innovation (new fabric masks, first FDA-cleared AI feature), and a sizable capital return program. Headwinds were present but generally moderate: SG&A growth (partly acquisition-related), a modest tax-rate headwind from global minimum tax, a small restructuring charge, and some lumpiness in ex-U.S. device comps and certain RCS verticals. On balance the highlights materially outweigh the lowlights, reflecting continued execution, margin expansion and strong cash returns to shareholders.Company Guidance
Revenue Growth
Group revenue of $1.42 billion, up 11% headline and 9% on a constant currency basis versus the prior-year quarter.
Earnings and Profitability
GAAP diluted EPS increased 16%; net income up 15%; operating profit rose 19% with operating margin improving to 36.3% of revenue (from 34% prior year).
Product and Category Performance
Global device sales increased ~11% (constant currency) and masks, accessories & other increased ~14% globally; U.S. masks/accessories grew ~16%; Europe/Asia/ROW masks/accessories grew 8% (constant currency).
Gross Margin Expansion and Supply Chain Gains
Reported gross margin was 32.3% for the quarter, up 110 basis points year-over-year and 30 basis points sequentially; management highlighted supply chain-driven productivity delivering 310 basis points of year-over-year gross margin improvement as a key driver.
Cash Generation and Balance Sheet Strength
Cash flow from operations of $340 million in the quarter; cash balance $1.4 billion; gross debt $664 million and net cash of $753 million; ~$1.5 billion available under revolver.
Capital Return to Shareholders
Returned $263 million to shareholders in the quarter via dividend and $175 million in share repurchases (704k shares); Board declared quarterly dividend of $0.60 per share; share repurchase program increased to >$600 million for FY2026.
R&D, Innovation and New Product Launches
Continued R&D investment (R&D ~6.4% of revenue this quarter, guided 6–7% FY); launched F30i Comfort and F30i Clear fabric masks with positive early feedback and ongoing rollouts.
AI and Digital Health Advances
Limited beta of Comfort Match (AI-enabled comfort setting recommender within myAir) — cited as ResMed's first FDA-cleared AI-enabled medical device aimed at improving short- and long-term adherence.
Clinical Education and Provider Engagement
Continuing Medical Education (CME) programs completed nearly 60,000 times (a 50% increase from the prior quarter) with 77% of provider survey respondents saying they intend to change clinical practice based on training.
Real-World Evidence Supporting Demand Tailwind
Claims analysis covering ~1.95 million patients: patients with both a GLP-1 and CPAP script were 10–11% more likely to start CPAP; 3% more likely to have a resupply event at 1 year and ~6.2% more likely at 3 years, indicating higher initiation and longer-term engagement.
Manufacturing and Distribution Expansion
Signed lease and started construction on a new U.S. distribution center in Indiana (on track for calendar 2027 opening) and expanded Calabasas plant to double U.S. manufacturing capacity — targeted to enable shipping to ~90% of U.S. customers in <2 business days.
RMD Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RMD Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jan 29, 2026 | $257.61 | $258.31 | +0.27% |
Oct 30, 2025 | $251.66 | $246.29 | -2.13% |
Jul 31, 2025 | $270.73 | $277.96 | +2.67% |
Apr 23, 2025 | $213.02 | $234.54 | +10.10% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Resmed (RMD) report earnings?
Resmed (RMD) is schdueled to report earning on Apr 23, 2026, After Close (Confirmed).
What is Resmed (RMD) earnings time?
Resmed (RMD) earnings time is at Apr 23, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RMD EPS forecast?
RMD EPS forecast for the fiscal quarter 2026 (Q3) is 2.81.